Jung Hoe Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jung Hoe Kim has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Byoung Sam Ko
Higher Education Center for Bioregulator Research, Chonnam National University, Gwangju, Korea
5 shared publicationsWoo Yong Shim
Department of Biological Sciences, Korea Advanced Institute of Science and Technology, 291 Daehak-ro (373-1 Guseong-dong), Yuseong-gu, Daejeon 305-701, Republic of Korea
5 shared publicationsByoung Hoon Yoon
Korea Advanced Institute of Science and Technology
4 shared publicationsSeung-Yeol Park
Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA
4 shared publicationsWoo Young Jeon
Biotechnology Process Engineering Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahangno, Yuseong-gu, Daejeon, 305-806, Korea
4 shared publications- In-Seok Yeo
Graduate School of Analytical Science and Technology, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, Republic of Korea
3 shared publications
Latest Publications
- Open Access
- 9 February 2021
- Published by Springer Nature in Bioprocess and Biosystems Engineering
- Vol. 44 (6) , 1147-1154
Conversion of l-arabinose to l-ribose by genetically engineered Candida tropicalis
L-Ribose, a starting material for the synthesis of l-nucleoside, has attracted lots of attention since l-nucleoside is responsible for the antiviral activities of the racemic mixtures of nucleoside enantiomers. In this study, the l-ribulose-producing Candida tropicalis strain was engineered for the conversion of l-arabinose to l-ribose. For the construction of a uracil auxotroph, the URA3 gene was excised by homologous recombination. The expression cassette of codon-optimized l-ribose isomerase gene from Acinetobacter calcoaceticus DL-28 under the control of the GAPDH promoter was integrated to the uracil auxotroph. The resulting strain, K1 CoSTP2 LsaAraA AcLRI, was cultivated with the glucose/l-arabinose mixture. At 45.5 h of fermentation, 6.0 g/L of l-ribose and 3.2 g/L of l-ribulose were produced from 30 g/L of l-arabinose. The proportion between l-ribose and l-ribulose was approximately 2:1 and the conversion yield of l-arabinose to l-ribose was about 20% (w/w). The l-ribose-producing yeast strain was successfully constructed for the first time and could convert l-arabinose to l-ribose in one-pot fermentation using the mixture of glucose and l-arabinose.
- 9 February 2021
- Published by Springer Nature in Bioprocess and Biosystems Engineering
- Vol. 44 (6) , 1147-1154
Open AccessConversion of l-arabinose to l-ribose by genetically engineered Candida tropicalis
L-Ribose, a starting material for the synthesis of l-nucleoside, has attracted lots of attention since l-nucleoside is responsible for the antiviral activities of the racemic mixtures of nucleoside enantiomers. In this study, the l-ribulose-producing Candida tropicalis strain was engineered for the conversion of l-arabinose to l-ribose. For the construction of a uracil auxotroph, the URA3 gene was excised by homologous recombination. The expression cassette of codon-optimized l-ribose isomerase gene from Acinetobacter calcoaceticus DL-28 under the control of the GAPDH promoter was integrated to the uracil auxotroph. The resulting strain, K1 CoSTP2 LsaAraA AcLRI, was cultivated with the glucose/l-arabinose mixture. At 45.5 h of fermentation, 6.0 g/L of l-ribose and 3.2 g/L of l-ribulose were produced from 30 g/L of l-arabinose. The proportion between l-ribose and l-ribulose was approximately 2:1 and the conversion yield of l-arabinose to l-ribose was about 20% (w/w). The l-ribose-producing yeast strain was successfully constructed for the first time and could convert l-arabinose to l-ribose in one-pot fermentation using the mixture of glucose and l-arabinose.
- Open Access
- 8 May 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 7273
Inhibition of poly-LacNAc biosynthesis with release of CMP-Neu5Ac feedback inhibition increases the sialylation of recombinant EPO produced in CHO cells
Sialylation of recombinant therapeutic glycoproteins modulates their pharmacokinetic properties by affecting their in vivo half-life. N-glycan branching on glycoproteins increases the number of potential attachment sites for sialic acid. Here, we introduce a new approach for increasing the sialylation of recombinant human erythropoietin (rhEPO) produced in CHO cells by modulating poly-N-acetyllactosamine (poly-LacNAc) biosynthesis. We did not observe an increase in rhEPO sialylation, however, until the feedback inhibition by intracellular cytidine monophosphate-N-acetylneuraminic acid (CMP-Neu5Ac), which is a limiting factor for sialylation, was released. Thus, we found that a combined approach inhibiting poly-LacNAc biosynthesis and releasing CMP-Neu5Ac feedback inhibition produces the most significant increase in rhEPO sialylation in metabolically engineered CHO cells. Furthermore, a detailed analysis of the resulting N-glycan structures using LC/MS revealed increased tri- and tetra- sialylated N-glycan structures accompanied by a reduction of di-sialylated N-glycan structures. These results validate our new approach for glycosylation engineering, and we expect this approach will be useful in future efforts to enhance the efficacy of other therapeutic glycoproteins.
- 8 May 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 7273
Open AccessInhibition of poly-LacNAc biosynthesis with release of CMP-Neu5Ac feedback inhibition increases the sialylation of recombinant EPO produced in CHO cells
Sialylation of recombinant therapeutic glycoproteins modulates their pharmacokinetic properties by affecting their in vivo half-life. N-glycan branching on glycoproteins increases the number of potential attachment sites for sialic acid. Here, we introduce a new approach for increasing the sialylation of recombinant human erythropoietin (rhEPO) produced in CHO cells by modulating poly-N-acetyllactosamine (poly-LacNAc) biosynthesis. We did not observe an increase in rhEPO sialylation, however, until the feedback inhibition by intracellular cytidine monophosphate-N-acetylneuraminic acid (CMP-Neu5Ac), which is a limiting factor for sialylation, was released. Thus, we found that a combined approach inhibiting poly-LacNAc biosynthesis and releasing CMP-Neu5Ac feedback inhibition produces the most significant increase in rhEPO sialylation in metabolically engineered CHO cells. Furthermore, a detailed analysis of the resulting N-glycan structures using LC/MS revealed increased tri- and tetra- sialylated N-glycan structures accompanied by a reduction of di-sialylated N-glycan structures. These results validate our new approach for glycosylation engineering, and we expect this approach will be useful in future efforts to enhance the efficacy of other therapeutic glycoproteins.
- 1 May 2018
- Published by Elsevier in Journal of Biotechnology
- Vol. 274, 9-14
Construction of genetically engineered Candida tropicalis for conversion of l -arabinose to l -ribulose
- 1 May 2018
- Published by Elsevier in Journal of Biotechnology
- Vol. 274, 9-14
Construction of genetically engineered Candida tropicalis for conversion of l -arabinose to l -ribulose
- Open Access
- 12 October 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 13059
Enhancing the sialylation of recombinant EPO produced in CHO cells via the inhibition of glycosphingolipid biosynthesis
Sialylation regulates the in vivo half-life of recombinant therapeutic glycoproteins, affecting their therapeutic efficacy. Levels of the precursor molecule cytidine monophospho-N-acetylneuraminic acid (CMP-Neu5Ac) are considered a limiting factor in the sialylation of glycoproteins. Here, we show that by reducing the amount of intracellular CMP-Neu5Ac consumed for glycosphingolipid (GSL) biosynthesis, we can increase the sialylation of recombinant human erythropoietin (rhEPO) produced in CHO cells. Initially, we found that treating CHO cells with a potent inhibitor of GSL biosynthesis increases the sialylation of the rhEPO they produce. Then, we established a stable CHO cell line that produces rhEPO in the context of repression of the key GSL biosynthetic enzyme UDP-glucose ceramide glucosyltransferase (UGCG). These UGCG-depleted cells show reduced levels of gangliosides and significantly elevated levels of rhEPO sialylation. Upon further analysis of the resulting N-glycosylation pattern, we discovered that the enhanced rhEPO sialylation could be attributed to a decrease in neutral and mono-sialylated N-glycans and an increase in di-sialylated N-glycans. Our results suggest that the therapeutic efficacy of rhEPO produced in CHO cells can be improved by shunting intracellular CMP-Neu5Ac away from GSL biosynthesis and toward glycoprotein sialylation.
- 12 October 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 13059
Open AccessEnhancing the sialylation of recombinant EPO produced in CHO cells via the inhibition of glycosphingolipid biosynthesis
Sialylation regulates the in vivo half-life of recombinant therapeutic glycoproteins, affecting their therapeutic efficacy. Levels of the precursor molecule cytidine monophospho-N-acetylneuraminic acid (CMP-Neu5Ac) are considered a limiting factor in the sialylation of glycoproteins. Here, we show that by reducing the amount of intracellular CMP-Neu5Ac consumed for glycosphingolipid (GSL) biosynthesis, we can increase the sialylation of recombinant human erythropoietin (rhEPO) produced in CHO cells. Initially, we found that treating CHO cells with a potent inhibitor of GSL biosynthesis increases the sialylation of the rhEPO they produce. Then, we established a stable CHO cell line that produces rhEPO in the context of repression of the key GSL biosynthetic enzyme UDP-glucose ceramide glucosyltransferase (UGCG). These UGCG-depleted cells show reduced levels of gangliosides and significantly elevated levels of rhEPO sialylation. Upon further analysis of the resulting N-glycosylation pattern, we discovered that the enhanced rhEPO sialylation could be attributed to a decrease in neutral and mono-sialylated N-glycans and an increase in di-sialylated N-glycans. Our results suggest that the therapeutic efficacy of rhEPO produced in CHO cells can be improved by shunting intracellular CMP-Neu5Ac away from GSL biosynthesis and toward glycoprotein sialylation.
- Open Access
- 28 September 2016
- Published by Oxford University Press (OUP) in Molecular BioSystems
- Vol. 12 (12) , 3611-3621
Glycomic profiling of targeted serum haptoglobin for gastric cancer using nano LC/MS and LC/MS/MS
Gastric cancer has one of the highest cancer mortality rates worldwide, largely because of difficulties in early-stage detection. Aberrant glycosylation in serum proteins is associated with many human diseases including inflammation and various types of cancer. Serum-based global glycan profiling using mass spectrometry has been explored and has already led to several potential glycan markers for several disease states. However, localization of the aberrant glycosylation is desirable in order to improve the specificity and sensitivity for clinical use. Here, we combined protein-specific immunoaffinity purification, glycan release, and MS analysis to examine haptoglobin glycosylation of gastric cancer patients for glyco-markers. Age- and sex-matched 60 serum samples (30 cancer patients and 30 healthy controls) were used to profile and quantify haptoglobin N-glycans. A T-test based statistical analysis was performed to identify potential glyco-markers for gastric cancer. Interestingly, abundances of several tri- and tetra-antennary fucosylated N-glycans were increased in gastric cancer patients. Additionally, structural analysis via LC/MS/MS indicated that the fucosylated complex type N-glycans were primarily decorated with antenna fucose, which can be categorized as sialyl-Lea or sialyl-Lex type structures. This platform demonstrates quantitative, structure-specific profiling of haptoglobin glycosylation for the purposes of biomarker discovery for gastric cancer.
- 28 September 2016
- Published by Oxford University Press (OUP) in Molecular BioSystems
- Vol. 12 (12) , 3611-3621
Open AccessGlycomic profiling of targeted serum haptoglobin for gastric cancer using nano LC/MS and LC/MS/MS
Gastric cancer has one of the highest cancer mortality rates worldwide, largely because of difficulties in early-stage detection. Aberrant glycosylation in serum proteins is associated with many human diseases including inflammation and various types of cancer. Serum-based global glycan profiling using mass spectrometry has been explored and has already led to several potential glycan markers for several disease states. However, localization of the aberrant glycosylation is desirable in order to improve the specificity and sensitivity for clinical use. Here, we combined protein-specific immunoaffinity purification, glycan release, and MS analysis to examine haptoglobin glycosylation of gastric cancer patients for glyco-markers. Age- and sex-matched 60 serum samples (30 cancer patients and 30 healthy controls) were used to profile and quantify haptoglobin N-glycans. A T-test based statistical analysis was performed to identify potential glyco-markers for gastric cancer. Interestingly, abundances of several tri- and tetra-antennary fucosylated N-glycans were increased in gastric cancer patients. Additionally, structural analysis via LC/MS/MS indicated that the fucosylated complex type N-glycans were primarily decorated with antenna fucose, which can be categorized as sialyl-Lea or sialyl-Lex type structures. This platform demonstrates quantitative, structure-specific profiling of haptoglobin glycosylation for the purposes of biomarker discovery for gastric cancer.
- 1 September 2014
- Published by Elsevier in Journal of Biotechnology
- Vol. 185, 28-36
Metabolic engineering of Pichia pastoris for production of hyaluronic acid with high molecular weight
- 1 September 2014
- Published by Elsevier in Journal of Biotechnology
- Vol. 185, 28-36
Metabolic engineering of Pichia pastoris for production of hyaluronic acid with high molecular weight
- 27 May 2014
- Published by Springer Nature in Journal of the Korean Society for Applied Biological Chemistry
- Vol. 57 (3) , 319-321
Immunological activities of cationic methylan derivatives
- 27 May 2014
- Published by Springer Nature in Journal of the Korean Society for Applied Biological Chemistry
- Vol. 57 (3) , 319-321
Immunological activities of cationic methylan derivatives
- 15 February 2013
- Published by Springer Nature in Bioprocess and Biosystems Engineering
- Vol. 36 (6) , 809-817
Effect of heterologous xylose transporter expression in Candida tropicalis on xylitol production rate
Xylose utilization is inhibited by glucose uptake in xylose-assimilating yeasts, including Candida tropicalis, resulting in limitation of xylose uptake during the fermentation of glucose/xylose mixtures. In this study, a heterologous xylose transporter gene (At5g17010) from Arabidopsis thaliana was selected because of its high affinity for xylose and was codon-optimized for functional expression in C. tropicalis. The codon-optimized gene was placed under the control of the GAPDH promoter and was integrated into the genome of C. tropicalis strain LXU1 which is xyl2-disrupted and NXRG (codon-optimized Neurospora crassa xylose reductase) introduced. The xylose uptake rate was increased by 37–73 % in the transporter expression-enhanced strains depending on the glucose/xylose mixture ratio. The recombinant strain LXT2 in 500-mL flask culture using glucose/xylose mixtures showed a xylose uptake rate that was 29 % higher and a xylitol volumetric productivity (1.14 g/L/h) that was 25 % higher than the corresponding rates for control strain LXU1. Membrane protein extraction and Western blot analysis confirmed the successful heterologous expression and membrane localization of the xylose transporter in C. tropicalis.
- 15 February 2013
- Published by Springer Nature in Bioprocess and Biosystems Engineering
- Vol. 36 (6) , 809-817
Effect of heterologous xylose transporter expression in Candida tropicalis on xylitol production rate
Xylose utilization is inhibited by glucose uptake in xylose-assimilating yeasts, including Candida tropicalis, resulting in limitation of xylose uptake during the fermentation of glucose/xylose mixtures. In this study, a heterologous xylose transporter gene (At5g17010) from Arabidopsis thaliana was selected because of its high affinity for xylose and was codon-optimized for functional expression in C. tropicalis. The codon-optimized gene was placed under the control of the GAPDH promoter and was integrated into the genome of C. tropicalis strain LXU1 which is xyl2-disrupted and NXRG (codon-optimized Neurospora crassa xylose reductase) introduced. The xylose uptake rate was increased by 37–73 % in the transporter expression-enhanced strains depending on the glucose/xylose mixture ratio. The recombinant strain LXT2 in 500-mL flask culture using glucose/xylose mixtures showed a xylose uptake rate that was 29 % higher and a xylitol volumetric productivity (1.14 g/L/h) that was 25 % higher than the corresponding rates for control strain LXU1. Membrane protein extraction and Western blot analysis confirmed the successful heterologous expression and membrane localization of the xylose transporter in C. tropicalis.
- 1 July 2012
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1820 (7) , 1141-1148
Globoside promotes activation of ERK by interaction with the epidermal growth factor receptor
- 1 July 2012
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1820 (7) , 1141-1148
Globoside promotes activation of ERK by interaction with the epidermal growth factor receptor
- 4 October 2011
- Published by Springer Nature in Bioprocess and Biosystems Engineering
- Vol. 35 (1-2) , 199-204
Enhancement of xylitol production in Candida tropicalis by co-expression of two genes involved in pentose phosphate pathway
The yeast Candida tropicalis produces xylitol, a natural, low-calorie sweetener whose metabolism does not require insulin, by catalytic activity of NADPH-dependent xylose reductase. The oxidative pentose phosphate pathway (PPP) is a major basis for NADPH biosynthesis in C. tropicalis. In order to increase xylitol production rate, xylitol dehydrogenase gene (XYL2)disrupted C. tropicalis strain BSXDH-3 was engineered to co-express zwf and gnd genes which, respectively encodes glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6-PGDH), under the control of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter. NADPH-dependent xylitol production was higher in the engineered strain, termed “PP”, than in BSXDH-3. In fermentation experiments using glycerol as a co-substrate with xylose, strain PP showed volumetric xylitol productivity of 1.25 g l−1 h−1, 21% higher than the rate (1.04 g l−1 h−1) in BSXDH-3. This is the first report of increased metabolic flux toward PPP in C. tropicalis for NADPH regeneration and enhanced xylitol production.
- 4 October 2011
- Published by Springer Nature in Bioprocess and Biosystems Engineering
- Vol. 35 (1-2) , 199-204
Enhancement of xylitol production in Candida tropicalis by co-expression of two genes involved in pentose phosphate pathway
The yeast Candida tropicalis produces xylitol, a natural, low-calorie sweetener whose metabolism does not require insulin, by catalytic activity of NADPH-dependent xylose reductase. The oxidative pentose phosphate pathway (PPP) is a major basis for NADPH biosynthesis in C. tropicalis. In order to increase xylitol production rate, xylitol dehydrogenase gene (XYL2)disrupted C. tropicalis strain BSXDH-3 was engineered to co-express zwf and gnd genes which, respectively encodes glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6-PGDH), under the control of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter. NADPH-dependent xylitol production was higher in the engineered strain, termed “PP”, than in BSXDH-3. In fermentation experiments using glycerol as a co-substrate with xylose, strain PP showed volumetric xylitol productivity of 1.25 g l−1 h−1, 21% higher than the rate (1.04 g l−1 h−1) in BSXDH-3. This is the first report of increased metabolic flux toward PPP in C. tropicalis for NADPH regeneration and enhanced xylitol production.